baber/WOPTO huggingface dataset:
Patent NZ-584275-A (NZ)
Title: Aqueous cyclosporine ophthalmic formulations
Inventor: COMBAL JEAN PHILIPPE
IPC: A61K31/573
Filed: 2008-10-08
Abstract: An aqueous ophthalmic formulation is disclosed, which comprises: (a) at least one cyclosporine having solubility in the formulation above about 28 microgram/mL; (b) a surface active agent which is a polysorbate; and (c) a nonionic tonicity agent which is a low molecular weight polyethylene glycol (PEG), which may be selected from the group consisting of PEG 200, PEG 300, PEG 400, and PEG 600; andwherein said aqueous formulation may further comprise: (d) one or more buffering agents and wherein the pH of the ophthalmic formulation is stable for at least 3 months; and wherein said ophthalmic formulation may further comprises: (e) at least one corticosteroid.
Patent NZ-585646-A (NZ)
Title: Method for increasing immunoreactivity of lymphocytes to antigen
Inventor: BAIER GOTTFRIED
IPC: A61K35/17
Filed: 2008-12-10
Abstract: A method to increase the immunoreactivity of cells of the immune system by reducing or inhibiting the Cbl-b function of the cells by using a short DNA or RNA sequence complementary to a part of the Cbl-b mRNA sequence. The method can be used to transiently increase the immunoreactivity of CD8+ or CD4+ T cells to a desired antigen. The inhibitory DNA or RNA sequences can be used to treat immunoinsufficiency in diseases such as AIDS, multiple myeloma, chronic lymphatic leukaemia, drug induced immunosuppression or cancer.
Patent NZ-588144-A (NZ)
Title: Method to determine responsiveness to antiviral therapy
Inventor: FILIPOWICZ WITOLD
IPC: C12Q1/68
Filed: 2009-04-20
Abstract: Disclosed is a method for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy that includes stimulation of Interferon (IFN) activity comprising analysing before antiviral therapy the level of expression of at least one gene from the following groups: i) LOC129607; RPLP0; and HERC5; (ii) HTATIP2; and IFI44L; (iii) IFI27; IFIT1; G1P2; IRF7; RSAD2; IFI44; OAS3; and IFIT2; (iv) LAMP3; HERC6; LOC286208; IFIT3; RALGPS1; PARP9; CCDC75; and CNP; (v) HIST1H2BG; HIST1H2BD; FLJ20035; PARP12; PNPT1; LGALS3BP; SAMD9; and LOC402560. The level of expression of the genes in the sample is compared to level of expression of the same genes in a control sample, wherein an increase in the level of expression of the genes in the sample from the subject before antiviral therapy relative to the level of expression of the same genes in the control sample indicates that the subject is not likely to be responsive to said antiviral therapy.
Patent NZ-589882-A (NZ)
Title: Method for the assembly of a tower and tower made of vertically stacked precast elements held in place by tensioned cables running inside the tower
Inventor: SKJAERBAEK POUL
IPC: E04C5/08
Filed: 2008-08-18
Abstract: 589882 A method for the assembly of a tower 3, where a number of pre-cast elements 5 are stacked vertically to build the tower 3, while parts of the elements 5 are forming the tower wall, where at least some of the elements 5 of the tower 3 are fixed in position and connected with a tower foundation by a number of respective assigned post-tensioned cables 8, which are running inside the tower 3, such that each of the at least some of the elements is connected with the tower foundation by its own cables 8, where the post-tensioned-cables 8 of the elements are pulled through the tower 3 without embedding in dedicated channels in the tower walls. The post-tensioned-cables 8 are fixed at certain points with the tower wall via damper-means to prevent their oscillation. The post-tensioned cables 8 of the elements, which are stacked upon a dedicated element, are guided in a circumferentially offset manner through the dedicated element to avoid interferences. At a given height of the tower 3, the respective assigned post-tensioned cables 8 of one of the pre-cast elements are positioned at a first radial distance from the tower wall, and the respective assigned post-tensioned cables 8 of another one of the pre-cast elements are positioned at a second radial distance from the tower wall, wherein the first radial distance differs from the second radial distance
Patent NZ-592943-A (NZ)
Title: Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
Inventor: BOCK ELISABETH
IPC: A61K38/17
Filed: 2009-11-17
Abstract: Disclosed are small peptides derived from a cytokine, interleukin-4 (IL-4), capable of binding to the IL-4 receptors and inhibiting macrophage activation, and thereby preventing the onset of inflammatory response. The invention further relates to use of said peptides for the production of a medicament for the treatment of different pathological conditions, wherein IL-4 plays a prominent role.
Patent NZ-593324-A (NZ)
Title: Method and device for harvesting energy from ocean waves
Inventor: NAIR BALAKRISHNAN
IPC: F03B13/12
Filed: 2010-01-07
Abstract: Disclosed is a device (100) for generating electricity from wave motion. The device (100) comprises at least one magnetostrictive element (106) and one or more electrically conductive coils or circuits (not shown) within the vicinity of one or more of the magnetostrictive elements (106). When deployed in a body of water (102), the motion of the body of water (102), including wave motion, causes changes in the strain of the one or more magnetostrictive elements (106). A corresponding change in magnetic field around the one or more magnetostrictive elements (106) generates an electric voltage and/or electric current in the one or more electrically conductive coils or circuits. The device (100) is arranged such that there is substantially no relative movement between the one or more magnetostrictive elements (106) and the one or more electrically conductive coils or circuits.
Patent NZ-595364-A (NZ)
Title: TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
Inventor: WILLIAMS MARK
IPC: A61K35/39
Filed: 2010-03-25
Abstract: 595364 The use of a purified or isolated KLK1, or a variant or active fragment thereof, in the preparation of a medicament for the treatment of pancreatic islet ?-cell dysfunction, where in the ?-cell dysfunction is diabetes.
Patent NZ-596918-A (NZ)
Title: A data jack module with a switch interconnecting circuit boards associated with each jack
Inventor: GRANSBURY KENNETH BASIL
IPC: H01R24/62
Filed: 2011-12-06
Abstract: Disclosed is a data jack module (10) for a patch panel. The module (10) includes a first data jack (20A) defining a first socket (22A) opening in a first direction (24A) and a second data jack (20B) adjacent the first data jack (20A). The second data jack (20B) defines a second socket (22B) opening in a second direction (24B) parallel to the first direction (24A). A primary circuit board is disposed in a primary plane substantially parallel to the first direction (24A) and secondary circuit board is disposed in a secondary plane. The secondary plane is substantially parallel to, and spaced apart from, the primary plane such that the first and second data jacks (20A, 20B) are sandwiched between the primary and secondary circuit boards. A switch assembly having an actuator (300) is disposed between the primary and secondary circuit boards. The switch assembly includes a group of primary switches on or adjacent the primary circuit board and a group of secondary switches on or adjacent the secondary circuit board.
Patent NZ-598093-A (NZ)
Title: ORGANIC-SULPHIDE COMPOSITION WITH MASKED ODOUR; dimethyl disulphide and dimethyl sulphoxide (or dimethyl disulfide and dimethyl sulfoxide)
Inventor: SCHMITT PAUL-GUILLAUME
IPC: C07C315/06
Filed: 2010-07-29
Abstract: 598093 Disclosed is composition comprising: a) at least one organic sulphide, optionally in oxide form, of general formula (1), in which R is chosen from a linear or branched alkyl radical containing from 1 to 4 carbon atoms, and a linear or branched alkenyl radical containing from 2 to 4 carbon atoms; n is equal to 0, 1 or 2; x is an integer chosen from 0, 1, 2, 3 or 4, preferably x represents 1, 2, 3 or 4; R' is chosen from a linear or branched alkyl radical containing from 1 to 4 carbon atoms, and a linear or branched alkenylene radical containing from 2 to 4 carbon atoms or, only when n = x = 0, a hydrogen atom; and b) at least one odour-masking agent comprising at least one monoester, at least one di- and/ or triester, at least one alcohol, at least one ketone and, optionally, at least one terpene.
Patent NZ-602274-A (NZ)
Title: Propynylaminoindan transdermal compositions
Inventor: WEN JIANYE
IPC: A61K9/70
Filed: 2011-03-21
Abstract: 602274 Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer comprising –COOH functional groups. In some instances, the matrix further includes a weak base that may be a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions. The transdermal composition may be used to treat Parkinson’s disease, Alzheimer’s disease, a memory disorder or stroke. The carboxylated polymer may be a acrylate-vinyl acetate copolymer.
Patent NZ-611260-A (NZ)
Title: Cellulosic and lignocellulosic structural materials and methods and systems for manufacturing such materials by irradiation
Inventor: MEDOFF MARSHALL
IPC: C12P5/02
Filed: 2009-04-28
Abstract: Disclosed is a method comprising: irradiating a cellulosic or lignocellulosic material, while the material is under a pressure above atmospheric pressure, so as to decrease the molecular weight of the cellulosic or lignocellulosic material. The radiation is preferably electron beam radiation and includes administering at least 2.4 Mrad of radiation.
Patent NZ-611898-A (NZ)
Title: Compounds for inhibiting mitotic progression
Inventor: CLAIBORNE CHRISTOPHER F
IPC: A61K31/55
Filed: 2007-11-14
Abstract: Disclosed herein is a process for preparing a compound of formula (1), said process comprising reacting a compound of formula (iv) with a compound of formula (v) to afford a compound of formula (1); specifically, wherein the reaction is carried out in the presence of methanol and potassium carbonate. Also disclosed is a process for preparing a sodium salt of the compound of formula (1).
Patent NZ-620569-A (NZ)
Title: A stabilising leg assembly for a ladder
Inventor: CHRISTOPHER JOHN KEMPTHORNE
IPC: E06C7/50
Filed: 2014-01-31
Abstract: 620569 A stabilising leg assembly for a ladder, the assembly comprising: a bracket for attachment to a ladder stile; a support leg pivotally attached to the bracket about a first axis; attachment means for attaching the bracket to the stile such that the bracket is pivotable relative to the stile about a second axis that is substantially perpendicular to the first axis; and a single support strut having a first end attached or attachable to the support leg, and a second end for attachment to a stile, the strut being movable about its first end and relative to the support leg.
Patent NZ-629860-A (NZ)
Title: Methods for treating cancer using tor kinase inhibitor combination therapy
Inventor: XU SHUICHAN
IPC: C07D487/04
Filed: 2014-09-02
Abstract: Disclosed herein it the use of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pytidin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer or isotopologue thereof, in the manufacture of a medicament for the treatment of cancer, wherein the treatment comprises administration of the 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pytidin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer or isotopologue thereof in combination with a second active ingredient selected from: a receptor tyrosine kinase inhibitor, a phosphoinositide 3-kinase pathway inhibitor, a serine/threonine-protein kinase and mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase pathway inhibitor, a DNA damaging agent, a DNA damage response agent, a cytoskeleton perturbagen, a protein stability inhibitor and a Bruton’s tyrosine kinase inhibitor to a patient having a cancer.
Patent NZ-703725-A (NZ)
Title: Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
Inventor: APT KIRK E
IPC: C12R1/90
Filed: 2009-03-19
Abstract: Disclosed is an isolated thraustochytrid microorganism of the thraustochytrid species deposited under ATCC Accession No. PTA-9695, PTA-9696, PTA-9697 or PTA-9698 or a strain derived therefrom, wherein the total fatty acids produced by said microorganism or strain derived therefrom comprise about 10% or less by weight eicosapentaenoic acid.
Patent NZ-703794-A (NZ)
Title: Settable compositions comprising unexpanded perlite and methods of cementing in subterranean formations
Inventor: BRENNEIS D CHAD
IPC: C09K8/46
Filed: 2011-12-21
Abstract: A method of cementing comprises placing a settable composition into a well bore and allowing the settable composition to set. The settable composition comprises unexpanded perlite in an amount of about 20% to about 50% by weight of cementitious components where unexpanded perlite is ground to a mean particle size of about 1 micron to about 100 microns, cement kiln dust in an amount of about 50% to about 80% by weight of the cementitious components, lime in an amount of about 1% to about 10% by weight of the cementitious components, and water. Also disclosed is method of cementing comprising: placing a settable composition. The settable composition comprises ground and unexpanded perlite in an amount sufficient to increase compressive strength of the settable composition, cement kiln dust, a cement and pumicite mixture comprising pumicite interground with cement, water; and allowing the settable composition to set.
Patent NZ-711982-A (NZ)
Title: Cytotoxic and anti-mitotic compounds, and methods of using the same
Inventor: WINTERS GEOFFREY C
IPC: A61P35/00
Filed: 2014-03-14
Abstract: Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound of structure (I) having cytotoxic and/or anti-mitotic activity.
Patent NZ-741896-A (NZ)
Title: System and method for medical device identifier
Inventor: SEMEN TIMOTHY
IPC: G06F21/30
Filed: 2013-10-01
Abstract: Disclosed is a method for managing data associated with la home medical equipment (HME) device provided to a patient. The method comprises receiving an HME device identifier associated with the HME device. The HME device identifier is a unique identifier to distinguish the HME device provided to the patient from other HME devices registered at a computer-based records management system. A processor searches the records management system for a patient record that is associated with the HME device identifier. The search is performed by using a search key based on the HME device identifier. The processor instructs accessing a patient record if the search failing to retrieve a patient record associated with the HME device identifier and the processor stores the HME device identifier into the accessed patient record.
Patent NZ-744383-A (NZ)
Title: Augmented reality systems and methods utilizing reflections
Inventor: HARRISES CHRISTOPHER
IPC: G06K9/80
Filed: 2017-01-19
Abstract: A display system comprises a wearable display device for displaying augmented reality content. The display device comprises a display area comprising light redirecting features that are configured to direct light to a user. The display area is at least partially transparent and is configured to provide a view of an ambient environment through the display area. The display device is configured to determine that a reflection of the user is within the user’s field of view through the display area. After making this determination, augmented reality content is displayed in the display area with the augmented reality content augmenting the user’s view of the reflection. In some embodiments, the augmented reality content may overlie on the user’s view of the reflection, thereby allowing all or portions of the reflection to appear to be modified to provide a realistic view of the user with various modifications made to their appearance.
Patent NZ-754946-A (NZ)
Title: Therapeutically active compounds and their methods of use
Inventor: ZAHLER ROBERT
IPC: C07D401/04
Filed: 2014-07-10
Abstract: Provided are methods for preparing compounds of Formula (Ia) which are useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Patent NZ-755033-A (NZ)
Title: Treatment of plants against disease
Inventor: CHRISTOPHER ARTHUR HENRY
IPC: A01P1/00
Filed: 2019-07-01
Abstract: Averting plant diseases is an ongoing battle in the agricultural and horticultural industries. Some diseases are minor; however others such as Xanthomonas present a serious problem, causing significant adverse economic impact. It is an object of the invention to go at least some way towards addressing this or to provide the public with a useful choice. The invention comprises a method of treating a plant against disease resulting from pathogens of Proteobacteria (eg Xanthomonas), comprising applying to the plant fatty acid and silicate.
Patent NZ-774490-A (NZ)
Title: Wireless access credential system
Inventor: DEXTER MATTHEW
IPC: H04L9/32
Filed: 2019-09-23
Abstract: An access control system and methods that leverage wireless access credentials to allow a user to securely gain access to a secured area using his or her mobile device. As such, a credentialed mobile device may permit access to the secured area without requiring a real-time connection to a credential management system and/or an administrative system. In one embodiment, a method of using a wireless access credential in an access control system is provided which includes encrypting, by a server system and using a symmetric cryptographic key stored by the server system and an access control edge device, a credential blob including the wireless access credential and a first public cryptographic key provided by a mobile device, wherein the first public cryptographic key and a first private cryptographic key are a first asymmetric cryptographic key pair stored by the mobile device; transmitting, by the server system, the encrypted credential blob to the mobile device for storage by the mobile device; establishing a secure wireless communication connection between the mobile device and an access control edge device including generating a shared cryptographic key; encrypting, by the mobile device and using the shared cryptographic key, a credential message including the encrypted credential blob; cryptographically signing, by the mobile device and using the first private cryptographic key, the encrypted credential message; transmitting, by the mobile device, the encrypted and signed credential message to the access control edge device; decrypting, by the access control edge device and using the shared cryptographic key, the encrypted and signed credential message to extract the encrypted credential blob; decrypting, by the access control edge device and using the symmetric cryptographic key, the encrypted credential blob to extract the wireless access credential; and unlocking a lock mechanism of an electronic lock associated with the access control edge device in response to successful authentication of the wireless access credential.
Patent PT-103972-A (PT)
Title: Vibrador temporizado para anti coagulação tópica
Inventor: MATIAS ANTONIO DE ALMEIDA
IPC: A61M25/00
Filed: 2008-02-18
Abstract: VIBRADOR TEMPORIZADO PARA ANTI COAGULAÇÃO TÓPICA, NOS SERES VIVOS, PODENDO SER USADO NA EPIDERME, NO INTERIOR DO CORPO OU AINDA EM SISTEMAS OU CATETERES IMPLANTADOS NO ORGANISMO OU A ELE LIGADOS COM CARÁCTER TRANSITÓRIO OU DEFINITIVO, CARACTERIZADO POR POSSUIR UM DISPOSITIVO DE VIBRAÇÃO (1) ACCIONADO PELOS TEMPORIZADORES (8) E (10) ACCIONADOS PELO INTERRUPTOR (5) PROGRAMADOS LOCALMENTE COM OS INTERRUPTORES (6) E (7) OU POR CONTROLO REMOTO POR UM DISPOSITIVO DE RÁDIO (11) ALIMENTADOS PELA BATERIA (3), SENDO QUE O DÍODO EMISSOR DE LUZ (4) ASSINALA QUE O DISPOSITIVO SE ENCONTRA LIGADO.
Patent PT-104056-A (PT)
Title: Saco reutilizável para carro de supermercado
Inventor: OLIVEIRA LIVIA MARIA ROLIM DE
IPC: B65D33/14
Filed: 2008-05-05
Abstract: UM SACO REUTILIZÁVEL PARA FAZER COMPRAS EM SUPERMERCADOS COM O OBJECTIVO DE SUBSTITUIR SACOS DE PLÁSTICO DESCARTÁVEIS, QUE CONTÉM UMA ALÇA (10) QUE POSSUI DUAS FENDAS (13) ONDE SÃO INTRODUZIDAS AS PONTAS DO SACO (16) ONDE SÃO COSTURADAS OU PRESAS POR OUTROS PROCESSOS.
Patent RO-84775-A (RO)
Inventor: OTTERSTEDT JAN E A
IPC: C10G11/18
Filed: 1982-02-26
Abstract: A cracking catalyst having good resistance to metal poisoning has at least two particle fractions of different particle sizes, the cracking catalyzing zeolite material being concentrated to the coarser particle size fractions, and the finer particle size fractions being formed from material having relatively lower or no or insignificant cracking catalyzing activity. The particles of the finer particle size fractions have a matrix of kaolin and amorphous alumina-silica and may contain for example, an SOx eliminating additive such as Al2O3, CaO and/or MgO. The coarser particle size fractions having cracking catalyzing effect have a mean particle size of from 80 to 125  mu m and the finer particle size fractions a mean particle size of from 30 to 75  mu m. The coarser particle size fractions have a zeolite content of at least 20 weight % and may have a zeolite content of up to 100 weight %, the remainder consisting essentially of material which has relatively lower or no or insignificant cracking-catalyzing activity and which consists of kaolin and amorphous alumina-silica. The catalyst mass as a whole may have a zeolite content of up to 50 weight %.
Patent RO-88703-A (RO)
Inventor: LING CHAI-KWAN N
IPC: A23K1/16
Filed: 1983-08-01
Abstract: PGRF has been synthesized. The invention provides synthetic peptides which are extremely potent in stimulating the release of pituitary GH in mammals and which have the formula: H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr- Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys- Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly- Glu-R34-Asn-Gln-Glu-R38-Gly-R40-R41-R  wherein R is OH or NH2, R34 is Ser or Ala, R38 is Arg or Ser, R40 is Ala or Arg and R41 is Arg, Arg-Ala, Arg-Ala-Arg, Arg-Ala-Arg-Leu or des-R41. These peptides or biologically active fragments thereof, or analogs thereof having well-known substitutions and/or additions, as well as nontoxic salts of any of the foregoing, may be administered therapeutically to mammals, including humans, and may be used diagnostically.
Patent RU-94017390-A (RU)
Inventor: TAKHCHIDI KH P
IPC: A61F9/00
Filed: 1994-05-12
Abstract: FIELD: medicine; ophthalmology. SUBSTANCE: method involves subscleral formation of channels for outflow of the intraocular fluid with access through the conjunctiva cut along the limb. The conjunctiva is cut within the planned scleral flat with radial knurling in the center, and the operation is ended with application of an interrupted suture on the knurled area edges with fixation to the limb. EFFECT: no scleral flat edge cicatrix; less traumatic operation.